In our subsequent in vitro study, we further explored combined gefitinib with bevacizumab significantly ameliorated MAPF-induced endothelial angiogenesis independent of EGFR status of lung adenocarcinoma patients (Figure 9). The gene discussed is EGFR; the disease is lung adenocarcinoma.